Alnylam Pharmaceuticals, a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of RNA interference (RNAi) therapeutics. Founded in 2002, Alnylam has made significant strides in the development of innovative treatments for rare genetic diseases, positioning itself as a leader in the industry. With a strong operational presence in key regions, including Europe and Asia, Alnylam focuses on delivering transformative medicines that target the underlying causes of diseases. Its core products, such as ONPATTRO and GIVLAARI, are distinguished by their unique mechanism of action, offering patients new hope where traditional therapies have fallen short. Recognised for its commitment to scientific excellence, Alnylam has achieved numerous milestones, including the first-ever approval of an RNAi therapeutic, solidifying its market position as a trailblazer in the biopharmaceutical landscape.
How does Alnylam Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Alnylam Pharmaceuticals's score of 44 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Alnylam Pharmaceuticals reported total carbon emissions of approximately 35,290,000 kg CO2e from Scope 1 and 9,933,000 kg CO2e from Scope 2 emissions. Additionally, their Scope 3 emissions included about 3,270,000 kg CO2e from business travel, 2,560,000 kg CO2e from employee commuting, and 1,107,000 kg CO2e from waste generated in operations. Alnylam has set ambitious reduction targets, aiming to decrease their Scope 1 and Scope 2 emissions by 30% from 2020 levels by the year 2030. This commitment reflects their proactive approach to addressing climate change and reducing their overall carbon footprint. In 2022, their emissions were approximately 4,095,000 kg CO2e for Scope 1 and 10,116,000 kg CO2e for Scope 2, indicating a slight decrease in Scope 1 emissions from 2021, which were about 3,905,000 kg CO2e. The company continues to disclose emissions data across all relevant scopes, demonstrating transparency in their climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Scope 1 | 3,054,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 8,518,000 | 0,000,000 | 00,000,000 | 0,000,000 |
Scope 3 | 3,064,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alnylam Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.